1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Eisai Co., Ltd.
  6. News
  7. Summary
    4523   JP3160400002


Delayed Japan Exchange  -  05/27 02:00:00 am EDT
5319.00 JPY   +0.89%
01:24aEisai Contributes to the Science of Cancer Medicine at ASCO 2022
12:54aEISAI : MHLW Grants Orphan Drug Designation in Japan to Mecobalamin Ultrahigh-Dose Formulation with Prospective Indication for Delaying the Progression of Disease and Functional Impairment of ALS
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Biogen shares slide as Medicare proposal restricts coverage of Alzheimer's treatments

01/12/2022 | 03:03pm EDT
FILE PHOTO: A sign marks a Biogen facility in Massachusetts

(Reuters) - The U.S. Medicare program's proposal to severely limit coverage of new Alzheimer's treatments including Biogen's Aduhelm threatens to hurt sales of the controversial drug and dim prospects for similar medicines in development by other companies.

In a draft decision on Tuesday, the Centers for Medicaid and Medicare Services (CMS), which runs the government health plan for people over age 65, said it would cover Aduhelm, and similar treatments, only for patients enrolled in approved clinical trials.

Shares of Biogen Inc were down more than 7% at $223.77 in afternoon trading, while shares of drugmakers developing similar treatments such as Eli Lilly and Co, Roche Holding AG and Eisai Co Ltd fell between 2% and 5%.

"It would appear that what is occurring is that cost is being put before the needs of Alzheimer's patients," Harry Johns, chief executive at the Alzheimer's Association patient advocacy group, told Reuters.

He estimated that out of the one million or so Alzheimer's patients who might now be eligible for Aduhelm, a few thousand at best could be enrolled in future CMS-approved trials, which will take years to conduct.

Aduhelm's high price has raised concerns over the toll it might take on the Medicare program since Alzheimer's is an age-related disease and around 85% of people who might use the drug are in the government plan.

Other health insurers have also questioned whether Aduhelm's benefits are worth the cost.

"We agree with CMS there is a need to obtain more clinical data on efficacy, which will be essential to ensuring these new medications deliver real value to patients before broadening access," Matt Eyles, president and CEO of trade group America's Health Insurance Plans, said.

Sales so far have been weak and Biogen last month cut the medication's list price by about half to $28,200 per year.

Biogen had been banking on the government's coverage decision to help drive sales of Aduhelm, which was approved by the U.S. Food and Drug Administration in June, despite a vote by the agency's outside advisers that the treatment's clinical benefits had not been proven.

Only one of Biogen's two pivotal trials showed Aduhelm can slow the rate of cognitive decline for Alzheimer's patients.

Medicare's draft decision essentially crushes any hopes of Aduhelm gaining traction any time soon, J.P. Morgan analyst Cory Kasimov said.

Analysts said the decision, if left in place, could result in negligible Aduhelm sales in 2022 and 2023. The treatment brought in sales of $300,000 in the third quarter, compared with the average analyst estimate of $10.8 million.

"It is imperative to change this draft decision to be aligned with reimbursement for other therapies for progressive diseases, where patients have immediate and equal access to medicines approved by the FDA," Biogen said in a statement.

Aduhelm, given as a monthly infusion, is a monoclonal antibody designed to remove a type of brain plaque associated with Alzheimer's Disease. Patients need to be monitored for potential side effects including brain swelling.

The agency's final coverage terms, due by April 12, are expected to apply to all drugs in the class.

Eli Lilly is conducting a head-to-head study comparing its experimental drug donanemab to Aduhelm and suggested it would not face similar restrictions if it demonstrates clear benefit.

"We expect that for drugs with established efficacy CMS will ensure access for all appropriate patients without creating further health inequities," Lilly said in an emailed statement.

(Reporting by Ankur Banerjee and Amruta Khandekar in Bengaluru and Deena Beasley in Los Angeles; Editing by Shinjini Ganguli and Bill Berkrot)

By Ankur Banerjee and Amruta Khandekar

© Reuters 2022
Stocks mentioned in the article
ChangeLast1st jan.
BIOGEN INC. 0.92% 204.22 Delayed Quote.-14.88%
EISAI CO., LTD. 0.89% 5319 Delayed Quote.-19.28%
ELI LILLY AND COMPANY 2.10% 313.46 Delayed Quote.13.48%
ON SEMICONDUCTOR CORPORATION 5.49% 59.33 Delayed Quote.-12.65%
ROCHE HOLDING AG -0.80% 330.4 Delayed Quote.-12.16%
All news about EISAI CO., LTD.
01:24aEisai Contributes to the Science of Cancer Medicine at ASCO 2022
12:54aEISAI : MHLW Grants Orphan Drug Designation in Japan to Mecobalamin Ultrahigh-Dose Formula..
05/20EISAI : “MOVICOL® HD” LaunchedA New Dosage Form Added to Polyethylene Glycol C..
05/19Global Coalition for Adaptive Research Announces the Discontinued Evaluation of Eritora..
05/16Eisai Reiterates Year-end Dividend on Higher FY22 Profit, Revenue as Global Brands Cont..
05/13TRANSCRIPT : Eisai Co., Ltd., Q4 2022 Earnings Call, May 13, 2022
05/12Nitto Denko Corporation Provides Consolidated Earnings Guidance for the Fiscal Year End..
05/12Eisai Co., Ltd. Announces Year End Dividend for the Year Ended March 31, 2022, Payable ..
05/09Eisai Initiates Preparation for New Drug Application, Based on the Results of an Invest..
More news
Analyst Recommendations on EISAI CO., LTD.
More recommendations
Sales 2022 738 B 5 799 M 5 799 M
Net income 2022 56 199 M 441 M 441 M
Net cash 2022 143 B 1 126 M 1 126 M
P/E ratio 2022 25,5x
Yield 2022 3,03%
Capitalization 1 512 B 11 872 M 11 872 M
EV / Sales 2022 1,85x
EV / Sales 2023 1,84x
Nbr of Employees 11 237
Free-Float 87,9%
Duration : Period :
Eisai Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EISAI CO., LTD.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 12
Last Close Price 5 272,00 JPY
Average target price 6 200,00 JPY
Spread / Average Target 17,6%
EPS Revisions
Managers and Directors
Haruo Naito Manager-Research & Development Promotions
Ryohei Yanagi Chief Financial Officer
Yasuhiko Katoh Chairman
Edward Stewart Geary Manager-Pharmaceutical Affairs
Lynn D. Kramer President-Neuroscience Drug Discovery Unit
Sector and Competitors
1st jan.Capi. (M$)
EISAI CO., LTD.-19.28%11 872
JOHNSON & JOHNSON4.90%472 231
PFIZER, INC.-8.57%302 932
ROCHE HOLDING AG-12.16%282 336
ABBVIE INC.11.20%266 074